Cash flow Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 06:30:00 13/02/2026 GMT			5-day change	1st Jan Change
2,937.50 ^JPY	+1.08%		+2.39%	-12.26%

02-03	AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review	MT
02-03	Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S	CI

4.YHrq-NzIBLUH12QM_bZ2U1HLAoG0tquQxMyigVCF4OY.OiLckpi6VuFJtCdJhcQfFCCAMrjk5MDZsr_E1mXjrpcGFKSiiK9rxmaDXA

Published financial data: DAIICHI SANKYO COMPANY, LIMITED

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2021	2022	2023	2024	2025
Revenues	963B	1,045B	1,278B	1,602B	1,886B
Total Revenues	963B	1,045B	1,278B	1,602B	1,886B
Cost of Goods Sold, Total	338B	353B	364B	415B	416B
Gross Profit	624B	692B	915B	1,186B	1,470B
Selling General & Admin Expenses, Total	333B	358B	471B	637B	731B
R&D Expenses	227B	260B	342B	365B	436B
Other Operating Expenses	-	-	234M	-27.28B	-8.63B
Other Operating Expenses, Total	560B	619B	813B	975B	1,159B
Operating Income	63.8B	73.03B	102B	211B	312B
Interest Expense, Total	-1.84B	-1.94B	-2.12B	-2.04B	-2.13B
Interest And Investment Income	2.71B	2.86B	9.73B	22.94B	26.78B
Net Interest Expenses	870M	922M	7.61B	20.9B	24.66B
Income (Loss) On Equity Invest.	168M	129M	-19M	184M	1.46B
Currency Exchange Gains (Loss)	904M	-219M	617M	428M	-4.03B
Other Non Operating Income (Expenses)	9.12B	1.71B	3.78B	5.08B	6.04B
EBT, Excl. Unusual Items	74.85B	75.57B	114B	238B	340B
Gain (Loss) On Sale Of Investments	-	-	5.91B	878M	16.26B
Gain (Loss) On Sale Of Assets	-	-	12.75B	106M	3.73B
Asset Writedown	-728M	-2.05B	-5.71B	-1.83B	-4.4B
EBT, Incl. Unusual Items	74.12B	73.52B	127B	237B	356B
Income Tax Expense	-1.71B	6.54B	17.67B	36.22B	59.87B
Earnings From Continuing Operations	75.83B	66.97B	109B	201B	296B
Net Income to Company	75.83B	66.97B	109B	201B	296B
Minority Interest	127M	-	-	-285M	-
Net Income - (IS)	75.96B	66.97B	109B	201B	296B
Net Income to Common Incl Extra Items	75.96B	66.97B	109B	201B	296B
Net Income to Common Excl. Extra Items	75.96B	66.97B	109B	201B	296B
Per Share Items
Net EPS - Basic	39.17	34.94	56.96	104.69	155.96
Basic EPS - Continuing Operations	39.17	34.94	56.96	104.69	155.96
Basic Weighted Average Shares Outstanding	1.94B	1.92B	1.92B	1.92B	1.9B
Net EPS - Diluted	39.11	34.91	56.91	104.62	155.87
Diluted EPS - Continuing Operations	39.11	34.91	56.91	104.62	155.87
Diluted Weighted Average Shares Outstanding	1.94B	1.92B	1.92B	1.92B	1.9B
Normalized Basic EPS	24.19	24.64	37.14	77.46	112.07
Normalized Diluted EPS	24.16	24.62	37.11	77.41	112
Dividend Per Share	27	27	30	50	60
Payout Ratio	64.44	77.24	50.02	33.42	38.65
American Depositary Receipts Ratio (ADR)	1	1	1	1	1
Supplemental Items
EBITDA	121B	131B	170B	271B	381B
EBITA	63.8B	73.03B	102B	211B	312B
EBIT	63.8B	73.03B	102B	211B	312B
Effective Tax Rate - (Ratio)	-2.3	8.9	13.93	15.27	16.84
Normalized Net Income	46.91B	47.23B	71.2B	149B	213B
Non-Cash Pension Expense	16.47B	18.22B	21.45B	25.86B	31.46B
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	227B	260B	342B	365B	436B

Fiscal Period: March	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	381B	662B	442B	647B	640B
Total Cash And Short Term Investments	381B	662B	442B	647B	640B
Accounts Receivable, Total	232B	267B	349B	454B	619B
Total Receivables	232B	267B	349B	454B	619B
Inventory	201B	218B	302B	438B	515B
Other Current Assets, Total	455B	198B	402B	635B	136B
Total Current Assets	1,268B	1,345B	1,495B	2,174B	1,909B
Net Property Plant And Equipment	265B	304B	349B	422B	499B
Long-term Investments	172B	186B	227B	339B	399B
Goodwill	77.71B	83.56B	98.33B	108B	241B
Other Intangibles, Total	173B	164B	160B	168B	104B
Deferred Tax Assets Long-Term	129B	138B	180B	249B	305B
Other Long-Term Assets, Total	3M	2M	4M	4M	3M
Total Assets	2,085B	2,221B	2,509B	3,461B	3,456B
Liabilities
Accounts Payable, Total	297B	325B	424B	557B	580B
Short-term Borrowings	391M	394M	20.4B	399M	399M
Current Portion of Long-Term Debt	20B	20B	21B	-	-
Current Portion of Leases	9.29B	10.69B	10.93B	12.44B	14.71B
Current Income Taxes Payable	6.1B	6.91B	21.47B	46.39B	60.37B
Other Current Liabilities	20.3B	32.49B	32.43B	95.55B	98.59B
Total Current Liabilities	354B	395B	530B	712B	754B
Long-Term Debt	163B	143B	102B	101B	101B
Long-Term Leases	33.05B	39.46B	38.84B	41.85B	39.84B
Pension & Other Post Retirement Benefits	3.93B	2.62B	1.31B	1.29B	1.56B
Deferred Tax Liability Non Current	17.52B	12.44B	12.65B	12.86B	11.07B
Other Non Current Liabilities	242B	278B	378B	903B	925B
Total Liabilities	813B	871B	1,063B	1,773B	1,833B
Common Stock, Total	50B	50B	50B	50B	50B
Additional Paid In Capital	94.49B	-	-	1.96B	-
Retained Earnings	1,277B	1,170B	1,232B	1,389B	1,457B
Treasury Stock	-261B	-37.48B	-36.81B	-36.63B	-147B
Comprehensive Income and Other	111B	168B	201B	284B	264B
Total Common Equity	1,272B	1,351B	1,446B	1,688B	1,623B
Minority Interest	-	-	-	429M	-
Total Equity	1,272B	1,351B	1,446B	1,689B	1,623B
Total Liabilities And Equity	2,085B	2,221B	2,509B	3,461B	3,456B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	1.92B	1.92B	1.92B	1.92B	1.86B
ECS Total Common Shares Outstanding	1.92B	1.92B	1.92B	1.92B	1.87B
Book Value / Share	663.85	704.76	754.09	880.4	869.69
Tangible Book Value	1,022B	1,103B	1,188B	1,411B	1,279B
Tangible Book Value Per Share	533.11	575.67	619.56	736.05	685.26
Total Debt	226B	214B	193B	156B	156B
Net Debt	-154B	-449B	-249B	-491B	-484B
Debt Equivalent of Unfunded Proj. Benefit Obligation	-23.73B	-32.84B	-43.71B	-67.05B	-71.14B
Minority Interest, Total (Incl. Fin. Div)	-	-	-	429M	-
Equity Method Investments, Total	1.44B	1.42B	1.31B	608M	5.6B
Inventories - Raw Materials, Total	36.59B	49.8B	105B	194B	253B
Inventories - Work In Process, Total	19.09B	18.73B	29.22B	24.64B	32.95B
Inventories - Finished Goods, Total	145B	149B	168B	220B	229B
Inventories - Others	1M	1M	1M	1M	2M
Full Time Employees	16.03K	16.46K	17.44K	18.73K	19.76K
Accumulated Allowance for Doubtful Accounts (Supple)	642M	924M	679M	965M	666M

Fiscal Period: March	2021	2022	2023	2024	2025
Net Income	74.12B	73.52B	127B	237B	356B
Depreciation & Amortization - CF	57.38B	58.24B	67.79B	59.65B	68.65B
Depreciation & Amortization, Total	57.38B	58.24B	67.79B	59.65B	68.65B
(Gain) Loss From Sale Of Asset	1.44B	7.75B	7.86B	2.12B	1.82B
(Income) Loss On Equity Investments - (CF)	-168M	-129M	19M	-184M	-1.46B
Other Operating Activities, Total	-33.64B	-21.89B	-46.95B	-105B	-109B
Change In Accounts Receivable	83.09B	-19.06B	-64.58B	-69.89B	-168B
Change In Inventories	-21.22B	-603M	-80.66B	-129B	-78.37B
Change In Accounts Payable	23.88B	13.29B	54.14B	120B	40.11B
Change in Other Net Operating Assets	7.32B	28.11B	50.06B	484B	-55.55B
Cash from Operations	192B	139B	115B	599B	53.84B
Capital Expenditure	-31.24B	-62.74B	-60.75B	-88.32B	-116B
Sale of Property, Plant, and Equipment	33M	5.26B	9.94B	519M	499M
Cash Acquisitions	-4.4B	-	-30.81B	-6.9B	-
Divestitures	-	-	8.3B	7.5B	5.25B
Sale (Purchase) of Intangible assets	-32.85B	-13.95B	-6.62B	-34.47B	-71.61B
Investment in Marketable and Equity Securities, Total	28.96B	283B	-186B	-165B	516B
Net (Increase) Decrease in Loans Originated / Sold - Investing	701M	379M	311M	173M	18M
Other Investing Activities, Total	-450M	39M	8.1B	3.82B	499M
Cash from Investing	-39.25B	212B	-258B	-283B	334B
Long-Term Debt Issued, Total	-	-	-	484M	-
Total Debt Issued	-	-	-	484M	-
Long-Term Debt Repaid, Total	-40.39B	-20.39B	-20.39B	-41.4B	-402M
Total Debt Repaid	-40.39B	-20.39B	-20.39B	-41.4B	-402M
Issuance of Common Stock	2M	-	-	-	-
Repurchase of Common Stock	-100B	-15M	-24M	-25M	-246B
Common Dividends Paid	-48.95B	-51.73B	-54.62B	-67.08B	-114B
Common & Preferred Stock Dividends Paid	-48.95B	-51.73B	-54.62B	-67.08B	-114B
Other Financing Activities, Total	-12.91B	-14.1B	-14.56B	-15.55B	-16.98B
Cash from Financing	-202B	-86.23B	-89.59B	-124B	-378B
Foreign Exchange Rate Adjustments	5.83B	16.6B	12.31B	21.42B	-17.58B
Miscellaneous Cash Flow Adjustments	1M	-	-	-9.22B	-1M
Net Change in Cash	-43.64B	282B	-221B	205B	-7.34B
Supplemental Items
Cash Interest Paid	1.84B	1.78B	2.08B	1.84B	1.93B
Cash Income Tax Paid (Refund)	24.52B	22.58B	46.25B	96.76B	108B
Levered Free Cash Flow	127B	271B	-194B	-185B	371B
Unlevered Free Cash Flow	128B	273B	-192B	-184B	373B
Change In Net Working Capital	-94.76B	-245B	257B	253B	-297B
Net Debt Issued / Repaid	-40.39B	-20.39B	-20.39B	-40.91B	-402M

Fiscal Period: March	2021	2022	2023	2024	2025
Profitability
Return on Assets	1.9	2.12	2.69	4.43	5.64
Return on Total Capital	2.6	2.98	3.98	7.59	10.76
Return On Equity %	5.88	5.11	7.81	12.83	17.86
Return on Common Equity	5.89	5.11	7.81	12.81	17.86
Margin Analysis
Gross Profit Margin %	64.85	66.19	71.57	74.07	77.96
SG&A Margin	34.6	34.29	36.86	39.77	38.76
EBITDA Margin %	12.59	12.56	13.27	16.93	20.18
EBITA Margin %	6.63	6.99	7.97	13.2	16.54
EBIT Margin %	6.63	6.99	7.97	13.2	16.54
Income From Continuing Operations Margin %	7.88	6.41	8.54	12.55	15.68
Net Income Margin %	7.89	6.41	8.54	12.53	15.68
Net Avail. For Common Margin %	7.89	6.41	8.54	12.53	15.68
Normalized Net Income Margin	4.87	4.52	5.57	9.27	11.27
Levered Free Cash Flow Margin	13.17	25.97	-15.16	-11.54	19.69
Unlevered Free Cash Flow Margin	13.29	26.09	-15.05	-11.46	19.77
Asset Turnover
Asset Turnover	0.46	0.49	0.54	0.54	0.55
Fixed Assets Turnover	3.76	3.67	3.92	4.16	4.1
Receivables Turnover (Average Receivables)	3.56	4.19	4.15	3.99	3.51
Inventory Turnover (Average Inventory)	1.81	1.69	1.4	1.12	0.87
Short Term Liquidity
Current Ratio	3.59	3.4	2.82	3.05	2.53
Quick Ratio	1.73	2.35	1.49	1.55	1.67
Operating Cash Flow to Current Liabilities	0.54	0.35	0.22	0.84	0.07
Days Sales Outstanding (Average Receivables)	102.65	87.1	87.9	91.78	103.84
Days Outstanding Inventory (Average Inventory)	201.88	216.3	260.81	325.94	418.3
Average Days Payable Outstanding	283.57	306.62	305.57	325.38	421.28
Cash Conversion Cycle (Average Days)	20.97	-3.22	43.14	92.34	100.86
Long Term Solvency
Total Debt/Equity	17.78	15.81	13.34	9.24	9.6
Total Debt / Total Capital	15.1	13.65	11.77	8.46	8.76
LT Debt/Equity	15.45	13.51	9.72	8.48	8.67
Long-Term Debt / Total Capital	13.12	11.67	8.58	7.76	7.91
Total Liabilities / Total Assets	39	39.19	42.37	51.21	53.03
EBIT / Interest Expense	34.69	37.62	48.08	103.82	146.58
EBITDA / Interest Expense	65.89	67.63	80.06	133.1	178.84
(EBITDA - Capex) / Interest Expense	48.9	35.31	51.4	89.74	124.21
Total Debt / EBITDA	1.87	1.63	1.14	0.58	0.41
Net Debt / EBITDA	-1.27	-3.42	-1.47	-1.81	-1.27
Total Debt / (EBITDA - Capex)	2.51	3.12	1.77	0.85	0.59
Net Debt / (EBITDA - Capex)	-1.72	-6.55	-2.29	-2.69	-1.83
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-1.96	8.56	22.36	25.28	17.77
Gross Profit, 1 Yr. Growth %	-2.25	10.79	32.3	29.66	23.95
EBITDA, 1 Yr. Growth %	-36.69	8.33	29.29	59.75	40.37
EBITA, 1 Yr. Growth %	-54.04	14.47	39.58	107.48	47.49
EBIT, 1 Yr. Growth %	-54.04	14.47	39.58	107.48	47.49
Earnings From Cont. Operations, 1 Yr. Growth %	-41.2	-11.68	63.04	84.1	47.13
Net Income, 1 Yr. Growth %	-41.15	-11.83	63.04	83.84	47.34
Normalized Net Income, 1 Yr. Growth %	-47.78	0.68	50.74	108.6	43.1
Diluted EPS Before Extra, 1 Yr. Growth %	-40.98	-10.74	63.02	83.83	48.99
Accounts Receivable, 1 Yr. Growth %	-25	14.93	30.91	30.1	36.31
Inventory, 1 Yr. Growth %	15.86	8.49	38.41	45.26	17.53
Net Property, Plant and Equip., 1 Yr. Growth %	7.38	14.62	14.75	20.86	18.22
Total Assets, 1 Yr. Growth %	-0.97	6.53	12.94	37.95	-0.14
Tangible Book Value, 1 Yr. Growth %	-3.32	8.02	7.66	18.81	-9.37
Common Equity, 1 Yr. Growth %	-2.59	6.2	7.03	16.76	-3.84
Cash From Operations, 1 Yr. Growth %	-2.24	-27.56	-17.75	423.31	-91.02
Capital Expenditures, 1 Yr. Growth %	-2.16	100.79	-3.17	45.39	31.63
Levered Free Cash Flow, 1 Yr. Growth %	-45.56	114.05	-171.41	-4.62	-301
Unlevered Free Cash Flow, 1 Yr. Growth %	-45.4	113.07	-170.61	-4.63	-303.12
Dividend Per Share, 1 Yr. Growth %	15.71	0	11.11	66.67	20
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	1.75	3.16	15.25	23.81	21.47
Gross Profit, 2 Yr. CAGR %	5.1	4.07	21.07	30.98	26.77
EBITDA, 2 Yr. CAGR %	-3.41	-17.19	18.35	43.71	49.75
EBITA, 2 Yr. CAGR %	-12.7	-27.47	26.4	70.18	74.94
EBIT, 2 Yr. CAGR %	-12.7	-27.47	26.4	70.18	74.94
Earnings From Cont. Operations, 2 Yr. CAGR %	-9.9	-27.94	20	73.25	64.58
Net Income, 2 Yr. CAGR %	-9.82	-27.97	19.89	73.13	64.58
Normalized Net Income, 2 Yr. CAGR %	-7.36	-27.49	23.19	77.33	72.78
Diluted EPS Before Extra, 2 Yr. CAGR %	-9.7	-27.42	20.63	73.11	65.5
Accounts Receivable, 2 Yr. CAGR %	-25.64	-7.16	22.66	30.5	33.17
Inventory, 2 Yr. CAGR %	6.81	12.11	22.54	41.79	30.66
Net Property, Plant and Equip., 2 Yr. CAGR %	7.61	10.94	14.68	17.76	19.53
Total Assets, 2 Yr. CAGR %	-0.07	2.71	9.69	24.82	17.37
Tangible Book Value, 2 Yr. CAGR %	0.95	2.19	7.84	13.1	3.77
Common Equity, 2 Yr. CAGR %	0.89	1.71	6.61	11.79	5.96
Cash From Operations, 2 Yr. CAGR %	44.51	-15.85	-22.81	107.47	-31.43
Capital Expenditures, 2 Yr. CAGR %	-6.98	40.16	39.44	18.65	38.34
Levered Free Cash Flow, 2 Yr. CAGR %	-30.78	7.95	23.63	-17.47	38.46
Unlevered Free Cash Flow, 2 Yr. CAGR %	-30.27	7.86	22.65	-17.94	39.18
Dividend Per Share, 2 Yr. CAGR %	7.57	7.57	5.41	36.08	41.42
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	0.08	3.97	9.2	18.5	21.76
Gross Profit, 3 Yr. CAGR %	0.54	6.96	12.74	23.87	28.59
EBITDA, 3 Yr. CAGR %	-0.49	0.36	-3.93	30.79	42.59
EBITA, 3 Yr. CAGR %	-5.79	-4.45	-9.78	49.11	62.25
EBIT, 3 Yr. CAGR %	-5.79	-4.45	-9.78	49.11	62.25
Earnings From Cont. Operations, 3 Yr. CAGR %	8.23	-10.5	-5.4	38.4	64.06
Net Income, 3 Yr. CAGR %	8.01	-10.5	-5.42	38.25	64.06
Normalized Net Income, 3 Yr. CAGR %	-3.29	-4.76	-7.46	46.84	65.09
Diluted EPS Before Extra, 3 Yr. CAGR %	8.8	-10.05	-4.95	38.82	64.67
Accounts Receivable, 3 Yr. CAGR %	0.07	-14.02	4.11	25.09	32.41
Inventory, 3 Yr. CAGR %	5.19	7.37	20.27	29.69	33.19
Net Property, Plant and Equip., 3 Yr. CAGR %	6.77	9.9	12.2	16.71	17.91
Total Assets, 3 Yr. CAGR %	3.19	2.08	6.01	18.4	15.87
Tangible Book Value, 3 Yr. CAGR %	4.94	3.26	3.98	11.38	5.05
Common Equity, 3 Yr. CAGR %	3.93	2.63	3.45	9.89	6.32
Cash From Operations, 3 Yr. CAGR %	21.02	14.8	-16.49	46.09	-27.14
Capital Expenditures, 3 Yr. CAGR %	10.12	20.22	23.9	41.39	22.83
Levered Free Cash Flow, 3 Yr. CAGR %	-9.3	0.85	-5.94	13.39	11.04
Unlevered Free Cash Flow, 3 Yr. CAGR %	-9.33	1.18	-6.35	12.79	11
Dividend Per Share, 3 Yr. CAGR %	4.99	4.99	8.74	22.8	30.5
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-0.49	1.81	5.89	11.49	13.95
Gross Profit, 5 Yr. CAGR %	-1.34	2.69	8.3	15.99	18.15
EBITDA, 5 Yr. CAGR %	-7.06	-0.75	6.66	15.86	14.73
EBITA, 5 Yr. CAGR %	-13.33	-3.86	5.97	20.37	17.58
EBIT, 5 Yr. CAGR %	-13.33	-3.86	5.97	20.37	17.58
Earnings From Cont. Operations, 5 Yr. CAGR %	-1.16	7.12	12.79	16.56	18.06
Net Income, 5 Yr. CAGR %	-1.59	4.61	12.62	16.53	18.04
Normalized Net Income, 5 Yr. CAGR %	-9.99	-5.07	6.54	22.13	18.79
Diluted EPS Before Extra, 5 Yr. CAGR %	-0.3	5.68	13.39	16.88	18.66
Accounts Receivable, 5 Yr. CAGR %	-1.38	2.84	8.56	1.6	14.88
Inventory, 5 Yr. CAGR %	6.84	7.31	11.81	20	24.32
Net Property, Plant and Equip., 5 Yr. CAGR %	1.18	6.9	9.87	12.98	15.07
Total Assets, 5 Yr. CAGR %	1.87	3.01	5.74	10.64	10.42
Tangible Book Value, 5 Yr. CAGR %	1.63	4.62	6.09	7.08	3.9
Common Equity, 5 Yr. CAGR %	0.65	2.81	5	6.2	4.45
Cash From Operations, 5 Yr. CAGR %	1.98	0.44	1.1	45.46	-22.82
Capital Expenditures, 5 Yr. CAGR %	2.86	20.43	21.02	19.59	29.49
Levered Free Cash Flow, 5 Yr. CAGR %	-5.55	51.7	2.66	-6.92	9.79
Unlevered Free Cash Flow, 5 Yr. CAGR %	-5.28	53.18	2.32	-6.95	9.73
Dividend Per Share, 5 Yr. CAGR %	6.19	2.96	5.15	16.47	20.79